202 results on '"Basik M"'
Search Results
2. Gender differences in how physicians access and process information
3. Leukocytes as a reservoir of circulating oncogenic DNA and regulatory targets of tumor‐derived extracellular vesicles
4. 99P Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with HER2-positive residual invasive breast cancer after neoadjuvant treatment (NAT)
5. 137P Combining protein and mRNA spatial profiles to identify distinct cell population in metaplastic breast cancer
6. 'Game Changer': Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management
7. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer
8. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes
9. Development of a multiplexed protein panel using a targeted proteomics approach for the study of CDK4/6 inhibitors resistance in hormone receptor positive breast cancer
10. 29P - Genomic Analysis of Drug Resistant Triple Negative Breast Cancers: A Translational Biopsy Study
11. Abstract OT1-09-01: Phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic response in patients with clinical/radiological complete response after neoadjuvant chemotherapy in order to explore the feasibility of breast-conserving surgery without surgery: NRG Oncology BR005
12. Abstract P2-02-02: Dynamics of ctDNA changes during neoadjuvant chemotherapy in triple-negative breast cancer patients
13. Abstract P6-08-08: Age-Related differences in clinicopathologic features and survival amongst women with triple negative breast cancer: A population-based study
14. 558 Poster - Development of a multiplexed protein panel using a targeted proteomics approach for the study of CDK4/6 inhibitors resistance in hormone receptor positive breast cancer
15. How iMALDI can improve clinical diagnostics
16. Abstract P1-09-19: Tumor RNA disruption index as a tool to predict response to neoadjuvant chemotherapy in breast cancer: Optimizing timing of biopsy
17. In vitro analysis of chromosomal instability in a colon cancer cell line
18. Abstract P6-03-03: The Q-CROC-3 project reveals novel genomic alterations in triple negative breast cancers in residual tumors after neoadjuvant chemotherapy
19. An integrated route to identifying new pathogenesis-based therapeutic approaches for trisomy 21 (Down Syndrome) following the thought of Jérôme Lejeune
20. MC13-0077 Array CGH analysis of paired metastatic biopsies obtained pre-treatment and at resistance to FOLFOX-bevacizumab in metastatic CRC patients
21. Genomic Analysis of Drug Resistant Triple Negative Breast Cancers: A Translational Biopsy Study
22. P3.02 Challenges in The Implementation of a Translational Research Biopsy-Driven Trial to Study Drug Resistance in Triple Negative Breast Cancer Patients
23. Technology & tools development
24. L6.2 Biopsy-Driven Trials to Identify Biomarkers of Therapeutic Resistance: Biospecimen Collection and Processing to Enable Multi-Dimensional Analysis
25. P3.07 Building the Organization Framework for Biopsy-Driven Translational Research: The Quebec Clinical Research Organization in Cancer (Q-Croc) Experience
26. Lectures
27. Extending Neoadjuvant Care through Multi-Disciplinary Collaboration: Proceedings from the Fourth Annual Meeting of the Canadian Consortium for Locally Advanced Breast Cancer
28. An integrated genomic approach identifies ARID1A as a candidate tumor-suppressor gene in breast cancer
29. Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.
30. Measurement of Pax2, TC21, CCND1, and RFS1 as predictive biomarkers for outcomes in the NCIC CTG MA.12 trial of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer.
31. Abstract P4-09-09: Serum SDF-1: Biomarker of Bone Relapse in the NCIC MA.14 Adjuvant Breast Cancer Trial
32. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes
33. False-negative HER2 tests with appropriate positive controls.
34. Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.
35. P19 A novel way of assessing health and vulnerability in older newly-diagnosed cancer patients: results of a pilot study
36. Combination of low plasma stromal cell-derived factor-1 and phosphorylated-CXCR4: independent prognostic marker for breast cancer.
37. A novel way of assessing health and vulnerability in older newly diagnosed cancer patients: preliminary results of an ongoing prospective pilot study.
38. A novel way of assessing health and vulnerability in older newly diagnosed cancer patients: An ongoing prospective pilot study
39. P.31 A novel way of assessing health and vulnerability in older newly diagnosed cancer patients: preliminary results of an ongoing prospective pilot study
40. Cullin-3 is a potential novel target for breast cancer chemoprevention and treatment
41. Identification of a molecular signature of radiographic response to cetuximab in patients (pts) with advanced colorectal cancer
42. p53 tumor suppressor gene status and the degree of genomic instability in sporadic colorectal cancers.
43. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
44. Identification of gene fusion transcripts by transcriptome sequencing in BRCA1-mutated breast cancers and cell lines
45. The use of ultra-dense array CGH analysis for the discovery of micro-copy number alterations and gene fusions in the cancer genome
46. Development of reverse phase protein microarrays for the validation of clusterin, a mid-abundant blood biomarker
47. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors
48. Prognosis and Recurrence Patterns of Anal Adenocarcinoma
49. An integrated route to identifying new pathogenesis-based therapeutic approaches for trisomy 21 (Down Syndrome) following the thought of Jérôme Lejeune
50. Clinical proteomics reveals vulnerabilities in non-invasive breast ductal carcinoma and drives personalized treatment strategies.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.